losartan / Generic mfg. - LARVOL DELTA

KEFALOS: The Effect of Losartan on Cephalexin (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Aleksi Tornio | Not yet recruiting ➔ Recruiting

Enrollment open

ANURIA FOLLOWING LEFT RENAL VEIN LIGATION IN A LONE KIDNEY: A SURGICAL MYTH IS VIGOROUSLY CHALLENGED - AN EVOLVING CASE REPORT FROM SEPTEMBER 2025 (ISN-WCN 2026) - "Outpatient medications included Dapagliflozin 10 mg daily, insulin, glipizide 20 mg daily, Losartan 25 mg daily, Prazosin 1 mg at bedtime and Dulaglutide 0.75 mg subcutaneous, weekly.During the open periaortic lymph node biopsy, the left renal vein was ligated to mobilize the inferior vena cava. In solitary kidney patients, the absence of collateral outflow makes ligation particularly dangerous and irreversible renal loss and need for permanent dialysis have been described. Recent studies continue to highlight the variability of renal tolerance and emphasize cautious, individualized operative planning regarding the practice of pre-emptive left renal vein ligation performed intraoperatively to improve surgical exposure and to control bleeding."

Case report • Clinical • Breast Cancer • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Solid Tumor • Type 2 Diabetes Mellitus • Urothelial Cancer

ANGIOTENSINOGEN GENE DELETION IN RENAL TUBULES AMERIOLATES TUBULOPATHY VIA ATTENUATION OF MITOCHONDRIAL DYSFUNCTION AND SENESCENCE IN DIABETIC KIDNEY DISEASE (ISN-WCN 2026) - "Furthermore, addition of Ang II/HG-induced senescent MDCK-derived conditioned medium to HK-2 cells facilitated the epithelial-to-mesenchymal transition in HK2 cells, which was reversed by losartan or apocynin treatment.Conclusion Deletion of Agt in RT attenuates tubulopathy, at least in part, through lessening ROS-mediated DNA damage, mitochondrial dysfunction and senescence in Akita mice. Parts of the data, will be presented at the Annual Meeting of the American Society of Nephrology, Houston, TX, USA, November 5-9, 2025."

Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • CCL2 • CXCL1 • NOX4 • TGFB1 • TNFA

DISTINCT TRANSCRIPTOMIC RESPONSES REVEAL A REGULATORY ROLE OF PIEZO1 IN PODOCYTE ADAPTATION TO MECHANICAL STRESS (ISN-WCN 2026) - "Podocyte injury in AII/HS-treated pPiezo1 KO mice was prevented by losartan and hydralazine, and partially ameliorated by the Rho kinase inhibitor fasudil.Conclusion Piezo1 is dispensable for podocyte maintenance under basal conditions but is essential for adaptation to mechanical stress. Its absence leads to severe podocyte injury, albuminuria, and glomerulosclerosis under both short- and long-term hypertensive stress. These findings highlight Piezo1 as a key mechanosensor in podocytes, with both insufficient and excessive activity potentially driving injury through distinct signaling pathways."

Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hypertension

DE NOVO IDIOPATHIC NODULAR GLOMERULOSCLEROSIS IN A KIDNEY TRANSPLANT PATIENT (ISN-WCN 2026) - "Early on, he began to present elevation of azotes without an apparent cause, for which a first renal biopsy was performed with an official report given by BANFF category 3: suspected (borderline) of cell rejection, in the same way a change of therapeutic scheme was carried out suspending mycophenolate and initiation of azathioprine, other infectious etiologies causing graft dysfunction were ruled out...To optimize antiproteinuric therapeutic management, ARA II was changed from losartan to irbesartan and iSGLT2 was initiated...Timely detection and appropriate management can contribute to improving the prognosis and quality of life of affected patients. More multicenter studies and case reports are needed to better understand the course, prognosis, and best therapeutic strategies for this rare entity."

Clinical • Amyloidosis • Cardiovascular • Chronic Kidney Disease • Cystic Fibrosis • Diabetic Nephropathy • Fibrosis • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Hypertension • IgA Nephropathy • Immunology • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Obesity • Respiratory Diseases • Transplant Rejection • Transplantation

ADJUNCTIVE HEMOADSORPTION WITH DNA 230 IN SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS WITH MULTIORGAN INVOLVEMENT: A CASE REPORT (ISN-WCN 2026) - "She exhibited SLE activity in renal, mucocutaneous, serosal, hematologic, and immunologic domains.She was started on ceftriaxone, paracetamol, N-acetylcysteine, hydrocortisone, calcium + vitamin D, losartan, and atorvastatin. She was discharged stable on day 25 on tapering corticosteroids with a scheduled renal biopsy.Renal, liver and inflammatory markersConclusion This case highlights the potential role of DNA 230 hemoadsorption as an adjunct to standard immunosuppression and dialysis in severe lupus with multiorgan involvement. By facilitating removal of cytokines and inflammatory mediators, hemoadsorption may accelerate recovery and improve organ function during lupus flares."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Heart Failure • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus

MONITORING OF POTASSIUM AND EGFR FOLLOWING RENIN ANGIOTENSIN SYSTEM INHIBITOR INITIATION – NECESSARY SAFETY GUIDELINE, OR COSTLY LIMIT TO OPTIMISING BP TREATMENT IN UK PRIMARY CARE? (ISN-WCN 2026) - "No patients had hyperkalaemia (K>6 mmol/L) or a significant decline in eGFR (>30% reduction from baseline).The average BP at the last prescribed dose was 130 mmHg systolic for those on ACEi, and 131 mmHg systolic for those on ARB.The cost of full optimisation (clinician, administrative and equipment) was estimated to be between £69.60-103.83 per patient optimised on ACEi (using Ramipril as an exemplar) and £54.55-82.58 for each patient optimised on ARB (using Losartan as an exemplar) – an average of £77.64/patient. In this cohort, concordance with the guideline was low. We did not identify any patients who had a significant safety event, and the overall change in potassium and eGFR was small.We propose that research in larger cohorts is undertaken to enable guidelines to be refined for a risk stratified, cost effective approach for repeat testing of eGFR and potassium after RASi initiation.This abstract was presented at the UK Kidney association..."

Clinical • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease • EGFR

LATE ONSET RENAL FAILURE FROM ANGIOTENSIN BLOCKADE: HOW CONCERNING IS LATE ONSET EGFR DECLINE WITH COMBINATION GUIDELINE-DIRECTED MEDICAL THERAPY IN CKD PATIENTS? (ISN-WCN 2026) - "Excluding a patient who received a new kidney transplant, and 2 patients currently on maintenance hemodialysis, the remaining 37 patients, M:F = 21:16, have a mean SCr after 7 years of 1.63 ± 0.68 (0.71 - 4.44) mg/dL.Case Report An 80-yo male with hypertension, dilated cardiomyopathy, diabetes mellitus and proteinuria was on stable combination GDMT of Losartan 50 mg BID, Carvedilol 12.5 mg BID and Spironolactone 25 mg/d for over 4 years. Such pharmacological prescriptions must be individualized, and drug discontinuation is indeed, sometimes, the right therapeutic choice to be made. Similar content was submitted to the American Society of Nephrology 2025 Kidney Week."

Clinical • Acute Kidney Injury • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • EGFR

IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MINIMAL CHANGE DISEASE - A CASE OF SUCCESSFUL RECHALLENGE (ISN-WCN 2026) - "After progression on carboplatin and paclitaxel, she was subsequently started on pembrolizumab, and demonstrated clinical response after three cycles, the last given 2 weeks before presentation...Given the temporal association and favorable oncologic response to ICI therapy, the diagnosis of MCD was attributed to pembrolizumab.ICI therapy was discontinued, and the patient was treated with oral prednisone 60 mg daily (tapered over 24 days) and rituximab (anti-CD20 antibody) 1 g IV given 2 weeks apart. Supportive therapy included bumetanide 1 g IV twice daily, losartan 12.5 mg daily, and atorvastatin 10 mg daily...In two cases, MCD relapsed following ICI re-challenge while in the third case, MCD remission was maintained with daily low-dose prednisone. Here, we report the first successful ICI re-challenge in a patient with ICI-associated MCD using a short course of low-dose prednisone bridging, achieving sustained renal remission and durable anti-tumor response."

Checkpoint inhibition • Clinical • CNS Disorders • Dyslipidemia • Endometrial Cancer • Glomerulonephritis • Immunology • Oncology • Solid Tumor

Impact of post approval quantitative changes in excipient composition on nitrosamine formation: De-risking strategy. (PubMed, Eur J Pharm Biopharm) - "In light of these recalls, we simulated the influence of post-approval level 1 and level 2 changes in excipient compositions on nitrosamine formation in metformin SR (sustained release) and losartan film coated tablets. Selecting formulation excipients with LNLs is critical for risk mitigation as was demonstrated in this study. To continue enjoying the regulatory flexibility in terms of reducing post approval variation submissions, it is paramount to assess the impact of nitrite load of excipients on the total nitrosamine burden of the product during product development."

Journal

High-performance thin-layer chromatographic method for simultaneous determination of some Angiotensin II Receptor Antagonists with amlodipine in spiked human plasma with UV detection. (PubMed, BMC Chem) - "A simple, sensitive, precise, and cost-effective high-performance thin-layer chromatographic method has been developed and validated for the simultaneous determination of Amlodipine and some Angiotensin II Receptor Antagonist drugs, including Olmesartan, Telmisartan, Candesartan, Losartan, and Irbesartan, in spiked human plasma. Amlodipine and the investigated Angiotensin II Receptor Antagonist drugs were successfully detected and quantified in both bulk drug and plasma samples, yielding high recovery percentages and low standard deviation values. The greenness of the proposed HPTLC method has been evaluated using the standards of greenness profile (AGREE and GAPI) and Eco-Scale."

Journal

Timing insights in losartan-induced pancreatitis: a clinical case report. (PubMed, Oxf Med Case Reports) - "This highlights the importance of differentiating drug-induced pancreatitis from idiopathic causes. This case highlights the importance of considering pancreatitis in differential diagnosis, particularly in patients lacking typical risk factors."

Journal • Cardiovascular • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hypertension • Hypertriglyceridemia • Pain • Pancreatitis

The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. (PubMed, Pharmacotherapy) - P2 | "Daily losartan reduced and delayed clinically significant paclitaxel-induced neuropathy while improving patient-reported outcomes, without additional toxicity. These findings support repurposing losartan as a low-cost PIPN prophylactic and justify validation in larger, multicenter trials."

Clinical • Journal • Breast Cancer • Gynecologic Cancers • Oncology • Pain • Peripheral Neuropathic Pain • Solid Tumor • NGF

Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer. (PubMed, Clin Cancer Res) - P2 | "GSK-3b blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor suppressive immune microenvironment."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • CEACAM6 • FN1 • TGFB1

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Children's Hospital Medical Center, Cincinnati | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Fibrosis • Genetic Disorders • Hematological Disorders • Immunology • Sickle Cell Disease

Evaluating the efficacy of losartan combined with ultrasound cavitation treatment at sequentially low and high mechanical indices for liver cancer (EASL 2026) - No abstract available

Clinical • Liver Cancer • Oncology • Solid Tumor

Severe Rhabdomyolysis Presenting in Multisystem Organ Failure in an Adolescent With SC Trait (SCCM 2026) - "His renal function recovered, with secondary hypertension managed with losartan and amlodipine. Mild spasticity in his lower extremities is managed with oral baclofen, and he has full use of all muscle groups. He has not had any recurrence of rhabdomyolysis to date. Pediatric rhabdomyolysis is rare, requiring a high index of suspicion, as the triad of myalgia, muscle weakness, and tea-colored urine is only present in approximately 10% of patients. Consideration of this diagnosis in pediatric patients presenting with AKI, particularly in the presence of associated conditions discussed above, including sickle cell trait, may lead to earlier recognition and prevention of MSOF."

Acute Kidney Injury • Cardiovascular • Epilepsy • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Musculoskeletal Pain • Myositis • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases

Methylene Blue as Rescue Therapy in Metformin-Associated Lactic Acidosis (SCCM 2026) - "He was compliant with metformin, tirzepatide, and losartan...While this case and others in the literature suggest a role for methylene blue in such scenarios, current evidence is limited to isolated case reports and small series. No large-scale clinical trials have confirmed its efficacy, so its use should be reserved for cases where standard therapies fail."

Acute Kidney Injury • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Renal Disease

Calcium-Phosphate Nephrocalcinosis and Progressive CKD in X-Linked Hypophosphatemia: Consequences of Lifelong Phosphate and Calcitriol Therapy (NKF-SCM 2026) - "She had congenital hypophosphatemic rickets, treated with calcium, phosphate, and calcitriol; nephrolithiasis managed with lithotripsy; hypertension on losartan; and parathyroidectomy for primary hyperparathyroidism (calcium 11.4 mg/dL, PTH 10 pg/mL)...She continues follow-up for stable stage 4 CKD due to calcium-phosphate nephrocalcinosis, managed with cinacalcet, calcitriol, and phosphate...Conventional therapy often causes nephrocalcinosis and progressive CKD. Burosumab, an anti-FGF23 monoclonal antibody, restores phosphate homeostasis and improves bone mineralization and clinical outcomes including a lower risk of nephrocalcinosis."

Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Hypertension • Metabolic Disorders • Nephrology • Renal Calculi • Renal Disease • FGF23

LYME MYOPERICARDITIS WITH EFFUSIVE-CONSTRICTIVE PHYSIOLOGY AND IMAGING-GUIDED RECOVERY (ACC 2026) - "Decision-Making: He was treated with ceftriaxone followed by doxycycline, six months of colchicine, and tapering NSAIDs. Guideline-directed therapy with losartan and metoprolol supported EF recovery to 56%... Lyme perimyocarditis can evolve into effusive-constrictive pericarditis. Colchicine use was associated with improved constrictive physiology. Imaging and hemodynamics guided conservative therapy and obviated surgery."

Cardiovascular • CNS Disorders • Depression • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lyme Disease • Pulmonary Disease

VERTICAL TRANSMISSION OF CHAGA'S CARDIOMYOPATHY IN A SECOND GENERATION IMMIGRANT (ACC 2026) - "She was stabilized with IV diuretics and started on guideline-directed medical therapy (losartan, metoprolol, furosemide, potassium). This case illustrates the importance of considering Chagas cardiomyopathy in young patients with unexplained NICM, even outside endemic regions. Screening in at-risk individuals is essential to early recognition and initiation of therapy."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Obesity • Pulmonary Disease • Respiratory Diseases

RESISTANT HYPERTENSION SECONDARY TO HYPERALDOSTERONISM LEADING TO REVERSIBLE PERFUSION DEFECTS DESPITE ANGIOGRAPHICALLY NORMAL LEFT HEART CATH (ACC 2026) - "Antihypertensive therapy including carvedilol, amlodipine, chlorthalidone, losartan, and spironolactone improved symptoms and controlled blood pressure. Chronic hyperaldosteronism may cause coronary vasoconstriction by altering smooth muscle and endothelial function, leading to vasospasm or microvascular dysfunction. This case highlights its link with reversible perfusion defects despite angiographically normal vessels."

Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

NEW SEVERE NONISCHEMIC CARDIOMYOPATHY IN A YOUNG WOMAN WITH POSSIBLE VERTICAL TRANSMISSION OF CHAGAS DISEASE (ACC 2026) - "She was stabilized with IV diuretics and started on guideline-directed medical therapy (losartan, metoprolol, furosemide, potassium). This case illustrates the importance of considering Chagas cardiomyopathy in young patients with unexplained NICM outside endemic regions. Screening in at-risk individuals is essential to early recognition and initiation of therapy."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Obesity • Pulmonary Disease • Respiratory Diseases

EARLY-ONSET, ASYMPTOMATIC NIFEDIPINE HEPATOTOXICITY: EXPANDING THE SPECTRUM OF CALCIUM CHANNEL BLOCKER LIVER INJURY (ACC 2026) - "He was started on intravenous nicardipine, later transitioned to oral nifedipine 90 mg daily plus losartan...Nifedipine was discontinued, replaced with hydrochlorothiazide, and liver enzymes normalized within 90 days... This case demonstrates that nifedipine can cause early, asymptomatic hepatocellular injury even in young, otherwise healthy individuals. Clinicians should maintain vigilance for unexplained transaminase elevations soon after initiation, and promptly discontinue the drug to prevent progression."

Hepatology • Immunology • Liver Failure

MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES (MINOCA) IN A PATIENT WITH CORONARY ARTERY ANEURYSMS (ACC 2026) - "He was transitioned to apixaban, clopidogrel, carvedilol and losartan. Our case highlights the presentation of MINOCA with CAA causing microvascular obstruction. Management of CAA can be challenging with limited data surrounding the medical and interventional therapies."

Clinical • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis